{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:37:44Z","timestamp":1758040664130,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.amjmed.2015.03.029","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T20:45:55Z","timestamp":1440621955000},"page":"e41-e42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0219-9055","authenticated-orcid":false,"given":"Mariano","family":"Andr\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Sivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliseo","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2015.03.029_bib1","doi-asserted-by":"crossref","first-page":"653.e7","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in\u00a0patients with gout: a cohort study","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2015.03.029_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.amjmed.2015.03.029_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/art.1780340203","article-title":"Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout","volume":"34","author":"Pascual","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2015.03.029_bib4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.27356","article-title":"Cellular characterization of the\u00a0gouty tophus: a quantitative analysis","volume":"62","author":"Dalbeth","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2015.03.029_bib5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2015.03.029_bib6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2009.122770","article-title":"Independent impact of\u00a0gout on the risk of acute myocardial infarction among elderly women: a population-based study","volume":"69","author":"De Vera","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2015.03.029_bib7","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2015.03.029_bib8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.amjmed.2015.03.029_bib9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment\u00a0relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2015.03.029_bib10","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.amjmed.2015.03.029_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2015.03.029_bib12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.amjmed.2015.03.029_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2015.03.029_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.22767","article-title":"Quality of care for gout in the US needs improvement","volume":"57","author":"Singh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2015.03.029_bib15","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2015.03.029_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2125.2010.03887.x","article-title":"Impact of allopurinol use on urate concentration and cardiovascular outcome","volume":"71","author":"Wei","year":"2011","journal-title":"Br J Clin Pharmacol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934315003484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934315003484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:05:59Z","timestamp":1757581559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934315003484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0002934315003484"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2015.03.029","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2015.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2015.01.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}